You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,496,554


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,496,554
Title: Purified mite allergen
Abstract:New purified mite allergens useful as pharmaceutical and diagnostic compositions for the treatment and diagnosis of mite allergic diseases are provided. Both allergens are contained in fecal extracts of mites in culture. The high molecular weight allergen has a weight average molecular weight of 70,000 to 80,000 as determined by sedimentation equilibrium. This is a glycoprotein containing more than about 70% sugar, and possesses allergen activity. The low molecular weight antigen has a molecular weight of 1,500 to 5,000 as determined by Sephadex G25 gel filtration. This is a glycoprotein containing more than about 40% sugar, and also possesses allergen activity.
Inventor(s): Oka; Satoru (Hiroshima, JP), Ono; Kazuhisa (Hiroshima, JP), Shigeta; Seiko (Hiroshima, JP), Wada; Takeshi (Hiroshima, JP)
Assignee: Fumakilla Limited (Tokyo, JP) Hiroshima University (Hiroshima, JP)
Application Number:08/283,905
Patent Claims:1. A purified and isolated mite allergen, said allergen possessing the following physicochemical and biological properties:

1 being isolated and purified from fecal extracts of mites in cultures;

2 being a glycoprotein containing more than 70% sugar;

3 having a weight-average molecular weight of 70,000 to 80,000 as determined by sedimentation equilibrium;

4 possessing allergen activity; and

5 being unstainable by Coomassie blue.

2. The purified and isolated mite allergen according to claim 1, wherein said allergen:

is freely soluble in water;

has a weight-average molecular weight of about 74,000;

has a specific volume of 0.6076;

has a sugar content of 77%;

has the amino acid composition and sugar composition shown in Table 5; and

possesses allergen activity.

3. The purified mite allergen according to claim 1, wherein said mite is Dermatophagoides pteronyssinus or Dermatophagoides farinae.

4. The purified and isolated mite allergen according to claim 1, which has the amino acid composition and sugar composition shown in Table 5.

5. A pharmaceutical composition for the treatment of mite allergic diseases, comprising as the active ingredient a pharmaceutically effective amount of the purified and isolated mite allergen according to claims 1, 3, or 4, and at least one pharmaceutically acceptable carrier or diluent.

6. A method of diagnosing mite allergic disease, comprising assaying the amount of histamine released from the basophils in a sample of a patient's blood in response to stimulation by the purified and isolated mite allergen according to claims 1, 3, or 4.

7. The method according to claim 6, wherein said method is hyposensitization therapy.

8. The method according to claim 7, wherein said mite allergen is used in formulation with an adjuvant and at least one additive selected from the group consisting of a stabilizer, an excipient, a dissolution aid, an emulsifier, a buffer, an analgesic, a preservative, and a colorant.

9. The method according to claim 7, wherein said mite allergen is administered intracutaneously, subcutaneously, intramuscularly, or intraperitoneally.

10. The method according to claim 7, wherein said mite allergen is used in the form of a troche, a sublingual tablet, an ophthalmic solution, an intranasal spray, a poultice, a cream, or a lotion.

11. The method according to claim 7, wherein said mite allergen is administered in an amount of less than about 20 .mu.g once per week.

12. A method of treatment for mite allergic diseases, comprising administering a pharmaceutically effective amount of the purified and isolated mite allergen according to claims 1, 3, or 4.

13. A diagnostic composition for mite allergic diseases, comprising as the active ingredient a diagnostically effective amount of the purified and isolated mite allergen according to claims 1, 3, or 4.

Details for Patent 5,496,554

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Greer Laboratories, Inc. N/A insects (whole body), mite dermatophagoides farinae Injection 101834 09/15/1958 ⤷  Try a Trial 2013-03-05
Greer Laboratories, Inc. N/A insects (whole body), mite dermatophagoides pteronyssinus Injection 101835 09/15/1958 ⤷  Try a Trial 2013-03-05
Jubilant Hollisterstier Llc N/A positive skin test control-histamine Injection 103891 03/13/1924 ⤷  Try a Trial 2013-03-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.